4//SEC Filing
Martin Samuel Bates 4
Accession 0001415889-24-017363
CIK 0000744218other
Filed
Jun 17, 8:00 PM ET
Accepted
Jun 18, 4:05 PM ET
Size
12.8 KB
Accession
0001415889-24-017363
Insider Transaction Report
Form 4
Martin Samuel Bates
SVP AND CFO
Transactions
- Exercise/Conversion
Common Stock
2024-06-14$10.38/sh+16,968$176,128→ 45,297 total - Exercise/Conversion
Common Stock
2024-06-14$9.02/sh+3,201$28,862→ 28,329 total - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2024-06-14−16,968→ 63,632 totalExercise: $10.38Exp: 2030-06-18→ Common Stock (16,968 underlying) - Sale
Common Stock
2024-06-14$35.42/sh−17,172$608,315→ 28,125 total - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2024-06-14−3,201→ 0 totalExercise: $9.02Exp: 2028-06-13→ Common Stock (3,201 underlying)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.89 to $35.76 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F2]As of June 13, 2022, the option is fully vested.
- [F3]As of June 18, 2024, the option is fully vested.
Documents
Issuer
Celldex Therapeutics, Inc.
CIK 0000744218
Entity typeother
Related Parties
1- filerCIK 0001709024
Filing Metadata
- Form type
- 4
- Filed
- Jun 17, 8:00 PM ET
- Accepted
- Jun 18, 4:05 PM ET
- Size
- 12.8 KB